Renal Cell Cacinoma Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Renal Cell Cacinoma Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Renal Cell Cacinoma Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Sutent(Sunitinib)
Nexavar(Sorafenib)
Votrient(Pazopanib)
Avastin(Bevacizumab)
Afinitor(Everolimus)
Inlyta(Axitinib)
Torisel(Temsirolimus)
Proleukin(Aldesleukin)
Segment by Application
Mucinous Tubular and Spindle Cell Carcinoma (MTSCC)
Multilocular Cystic Clear Cell Renal Cell Carcinoma
Tubulocystic Renal Cell Carcinoma
Thyroid-Like Follicular Renal Cell Carcinoma
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Merck & Co., Inc.
Exelixis Inc
Argus Therapeutics, Inc.
Bristol-Myers Squibb
Genentech
Immatics Biotechnologies
AVEO Oncology
Eisai
Acceleron
Rexahn Pharmaceuticals
Bionomics
Cerulean Pharma Inc
Celldex Therapeutics
TVAX Biomedical
TRACON Pharmaceuticals
